BioSpect
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

ENTOD Pharmaceuticals announces Project AXIOM for myopia therapeutics

25 August 2026 | News

For an investigational topical ophthalmic candidate designed to modulate retinal dopaminergic signalling

Mumbai-based ENTOD Pharmaceuticals has announced Project AXIOM, an India-led research programme exploring dopaminergic modulation as a next-generation therapeutic approach to progressive myopia.

At its centre is AKMYX-101, an investigational topical ophthalmic candidate designed to modulate retinal dopaminergic signalling, with the aim of influencing excessive axial elongation, a key driver of progressive myopia.

The programme will combine advanced formulation science, ocular pharmacokinetics, target-engagement studies and preclinical research, with the ambition of indigenously developing from India a potentially world-first ophthalmic therapy of its kind.

Nikkhil K Masurkar, CEO & Global Head of Innovation, ENTOD Pharmaceuticals, said “As India moves towards Viksit Bharat and Aatmanirbhar Bharat, our pharmaceutical industry must aspire not only to manufacture for the world, but to originate new science and therapeutic innovation for the world. Project AXIOM represents our ambition to take bold ophthalmic science conceived and developed in India towards global patients.”

Project AXIOM remains an early-stage investigational programme and will undergo the necessary preclinical, safety, regulatory and clinical development before its therapeutic potential can be established.